How does Dynavax Technologies Corporation turn its adjuvant science into recurring vaccine revenue?
Dynavax combines proprietary adjuvant platform with partnered vaccines to boost efficacy and margins; by 2025 it reported growing commercial sales and strategic supply agreements that supported a $2.2 billion valuation late 2025.
Its revenue mixes product sales and licensing fees, with retail pharmacy expansion and manufacturing scale lowering unit costs and improving gross margins; focus on adjuvant-led differentiation makes demand stick.
See product detail: Dynavax SWOT Analysis
What Does Dynavax Actually Sell?
Dynavax Technologies Corporation sells vaccines and an immune-stimulating adjuvant platform; its two commercial offerings are HEPLISAV-B, a two-dose adult hepatitis B vaccine, and CpG 1018, a TLR9 adjuvant licensed to partners to boost other vaccines' effectiveness.
Core commercial products
Dynavax's main product is the HEPLISAV-B vaccine for adults, approved in the US, EU, and UK; its platform product is the CpG 1018 adjuvant sold inside HEPLISAV-B and licensed to vaccine makers to enhance immune response.
Primary customers and partners
Customers include adult immunization programs, public health agencies, clinicians, and pharmaceutical partners that integrate CpG 1018 into licensed vaccines and candidates across COVID-19 and other indications.
Value delivered
HEPLISAV-B reduces dosing from three doses over six months to two doses in one month, improving compliance and faster protection; CpG 1018 amplifies antibody and cellular responses, increasing vaccine efficacy and dose-sparing potential.
Why customers pick these offerings
Buyers choose HEPLISAV-B for a shorter schedule and higher seroprotection rates in adults; partners license CpG 1018 because it is a validated TLR9 adjuvant with real-world use in approved vaccines, shortening development risk and improving immunogenicity.
Key 2025 facts: HEPLISAV-B remains Dynavax's revenue driver with reported 2025 net product sales of $145 million; CpG 1018 licensing and collaboration revenue contributed $60 million in 2025, per company filings and partner disclosures. For commercial context, HEPLISAV-B's two-dose schedule achieves seroprotection rates >90% in adults within one month versus historical three-dose comparators; CpG 1018 appears in multiple partner programs, including licensed COVID-19 vaccines globally. See more in this company overview: Where Dynavax Company Is Going
Dynavax SWOT Analysis
- Complete SWOT Breakdown
- Fully Customizable
- Editable in Excel & Word
- Professional Formatting
- Investor-Ready Format
How Does Dynavax Run Day to Day?
Dynavax runs day-to-day with a lean commercial sales force focused on HEPLISAV-B uptake and a strategic R&D group advancing CpG 1018-based programs; operations prioritize scalable manufacturing via internal and contract partners while steering a diversified vaccine pipeline.
Operating model: lean commercial, focused R&D
Dynavax combines a small, targeted sales team with centralized R&D to keep fixed costs low and speed decisions on clinical priorities; daily work centers on driving HEPLISAV-B adoption and advancing CpG 1018 programs.
Product delivery: channel-led vaccine access
HEPLISAV-B is distributed through retail pharmacies, Integrated Delivery Networks (IDNs), and dialysis centers; field reps and distributor contracts ensure stock, billing, and on-site administration workflows run smoothly.
Production and sourcing: hybrid manufacturing
Manufacturing for the CpG 1018 adjuvant and vaccine fill-finish uses a mix of in-house capacity and contract manufacturing organizations (CMOs) to match demand surges and support regulatory filings.
Sales channels: pharmacies, IDNs, dialysis centers
Retail pharmacies are the largest channel-Dynavax held 63 percent of retail pharmacy market share for HEPLISAV-B by late 2025-while IDNs and dialysis centers cover institutional and specialty routes.
Key assets and partnerships: supply chain and funding sponsors
Core assets include CpG 1018 manufacturing know-how, clinical data packages, and partnerships with CMOs and hospital systems; Department of Defense funding supports the plague vaccine program and diversifies revenue streams.
What makes it work: focused commercialization plus pipeline optionality
Daily efficiency comes from concentrating sales efforts where impact is highest (retail pharmacies) and using CMOs to scale production while R&D advances pipeline candidates to reduce single-product risk.
How Dynavax Runs Day to Day
Dynavax operates as a channel-focused commercial business supported by targeted R&D: sales reps push HEPLISAV-B through pharmacies, IDNs, and dialysis centers while manufacturing and clinical teams secure supply and advance CpG 1018 programs including a shingles candidate and a DoD-funded plague vaccine.
- Core operating model: lean sales force plus strategic R&D advancing CpG 1018 pipeline
- Product delivery: HEPLISAV-B flows via retail pharmacies, IDNs, dialysis centers with distributor and on-site administration support
- Main channel/support: retail pharmacies (holding 63 percent retail market share for HEPLISAV-B in late 2025) and CMO partnerships
- Efficiency driver: hybrid manufacturing scalability and focused commercial efforts reduce costs and accelerate uptake
Read more context in What Dynavax Company Stands For
Dynavax PESTLE Analysis
- Covers All 6 PESTLE Categories
- No Research Needed – Save Hours of Work
- Built by Experts, Trusted by Consultants
- Instant Download, Ready to Use
- 100% Editable, Fully Customizable
How Does Money Come In at Dynavax?
Dynavax Technologies company earns revenue mainly from net product sales of its HEPLISAV-B vaccine, supplemented by licensing/supply fees for its CpG 1018 adjuvant and government contracts for vaccine development. The model mixes high-margin commercial vaccine sales, partner licensing, and non-dilutive R&D funding.
Main revenue: HEPLISAV-B product sales
Net product sales of HEPLISAV-B are the dominant engine; 2024 sales totaled 268.4 million dollars and 2025 revenue is guided to 315-325 million dollars. High gross margins-reported near 84 percent in 2025-make HEPLISAV-B the core profit driver for Dynavax vaccine technology.
Additional streams: CpG 1018 licensing and government contracts
Dynavax licenses its CpG 1018 adjuvant to global vaccine partners under supply and licensing agreements, generating recurring fees and milestone payments. The company also wins non-dilutive government contracts-such as the roughly 30 million dollar US Department of Defense plague vaccine award-that fund pipeline work.
Pricing and monetization model
HEPLISAV-B is sold through one-time vaccine unit sales to providers and distributors at list and contracted prices, producing high gross margins. CpG 1018 is monetized via supply contracts, per-dose pricing, and licensing fees tied to partner programs.
Primary revenue driver: volume and margin on HEPLISAV-B
Revenue hinges on vaccination uptake and market share for HEPLISAV-B, pricing power, and manufacturing scale. Licensing deal flow and government program wins provide revenue smoothing and non-dilutive R&D funding.
How Dynavax Turns Science into Revenue
Dynavax converts clinical and manufacturing assets into cash primarily through HEPLISAV-B sales, secondarily via CpG 1018 licensing/supply, and bolsters runway with government contracts; management guided adjusted EBITDA of at least 80 million for 2025 based on this mix.
- HEPLISAV-B net product sales: main revenue stream, 268.4 million in 2024 and 315-325 million guided for 2025.
- CpG 1018 adjuvant: licensing and supply fees to vaccine partners, recurring and milestone-based revenue.
- Monetization model: unit vaccine sales plus per-dose and licensing fees for adjuvant; government contracts provide non-dilutive funding.
- Strongest driver: vaccine volume and mix plus high gross margin (~84 percent in 2025) on HEPLISAV-B.
Related context on ownership and corporate background is available at Who Owns Dynavax Company
Dynavax SOAR Analysis
- Complete SOAR Analysis
- Effortlessly Communicate Your Business Strategy
- Investor-Ready Format
- 100% Editable and Customizable
- Clear and Structured Layout
What Makes Dynavax's Model Strong or Fragile?
Dynavax Technologies company combines a technical moat in CpG 1018 adjuvant science with commercial traction from HEPLISAV-B, but it was exposed by product concentration until the Sanofi acquisition in December 2025. Strengths include pricing power and physician preference for the two-dose HEPLISAV-B vaccine; vulnerabilities were reliance on one commercial product and pipeline delivery timing.
Technical moat and market share
Dynavax vaccine technology centers on the CpG 1018 adjuvant, which boosts immune response and shortens dosing; by Q3 2025 HEPLISAV-B vaccine captured approximately 46 percent of the US adult hepatitis B market, underpinning pricing power and commercial leverage.
Manufacturing and regulatory foothold
Manufacturing scale for HEPLISAV-B and an FDA approval history for CpG 1018 adjuvant create barriers to entry; physician preference for the two-dose regimen raises switching costs and supports stable revenues.
Concentration risk and pipeline timing
Before acquisition, Dynavax depended heavily on HEPLISAV-B for commercial revenue while its vaccine development pipeline - shingles and Tdap candidates - awaited clinical proof points and regulatory milestones.
Durability after acquisition
After Sanofi signed a definitive agreement on December 24, 2025 to acquire Dynavax for about 2.2 billion dollars, the single-product fragility was neutralized and the model in 2026 is assessed as highly robust given validation by a top-tier pharma buyer.
Why the model holds or breaks
Dynavax's business model works because CpG 1018 and HEPLISAV-B deliver clinical and commercial differentiation; it could weaken if pipeline candidates failed or if competitors eroded the adjuvant advantage before the Sanofi acquisition.
- Technical moat in CpG 1018 adjuvant and two-dose HEPLISAV-B deliver pricing power
- Commercial scale and physician preference are the most important capabilities
- High revenue concentration on HEPLISAV-B was the primary dependency
- Post-acquisition by Sanofi the model looks resilient rather than exposed
Read more context on market positioning and served customers in this related piece: Who Dynavax Company Serves
Dynavax VRIO Analysis
- Covers VRIO Analysis in Details
- Structured for Consultants, Students, and Founders
- 100% Editable in Microsoft Word & Excel
- Instant Digital Download – Use Immediately
- Compatible with Mac & PC – Fully Unlocked
Related Blogs
Frequently Asked Questions
Dynavax sells two commercial offerings: HEPLISAV-B and CpG 1018. HEPLISAV-B is a two-dose adult hepatitis B vaccine, while CpG 1018 is a TLR9 adjuvant licensed to partners to improve other vaccines' effectiveness. The company uses both products as its core commercial engine.
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site - including articles or product references - constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.